Screener
Sutro Biopharma STRO Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 220,972 | 150,926 |
| Property and equipment, net | 9,363 | 10,648 |
| Operating lease right-of-use assets | 9,707 | 10,903 |
| Other non-current assets | 1,088 | 495 |
| Restricted cash | 858 | 858 |
| Total assets | $241,988 | $173,830 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's deferred tax assets and other non-current assets?
- Sutro Biopharma (STRO) reported deferred tax assets and other non-current assets of $1.09M in Q1 2026.
- How has Sutro Biopharma's deferred tax assets and other non-current assets changed year-over-year?
- Sutro Biopharma's deferred tax assets and other non-current assets increased by 1180.0% year-over-year, from $85K to $1.09M.
- What is the long-term trend for Sutro Biopharma's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Sutro Biopharma's deferred tax assets and other non-current assets has grown at a -25.3% compound annual growth rate (CAGR), from $2.12M to $495K.
Ask your AI about Sutro Biopharma's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude